BIOSeedin Winter Innovation Partnering Summit in San Francisco
Analysis based on 8 articles · First reported Feb 02, 2026 · Last updated Feb 11, 2026
The BIOSeedin Winter Innovation Partnering Summit, with key participation from ACROBiosystems and sponsorship from major pharmaceutical companies like Eli Lilly and Company and Roche, fosters collaboration and licensing opportunities in the biopharmaceutical sector. This event is expected to accelerate drug development and global health advancements, positively impacting the market sentiment for participating biotech and pharma firms.
The BIOSeedin Winter Innovation Partnering Summit, held in San Francisco on January 11, 2026, ahead of J.P. Morgan 2026, focused on 'Global Matching of Innovative Assets'. ACROBiosystems was a key strategic partner, joining various enterprises. The summit gathered over 500 delegates from multinational pharma, investors, and biotech firms to explore licensing opportunities and globalization strategies. Sponsored by Eli Lilly and Company, Roche, and Fangda Partners, the event featured discussions on global expansion of locally-developed drugs, clinical development, and market access. Senior leaders from companies including Pfizer, AbbVie, Daiichi Sankyo, Takeda Pharmaceutical Company, Bayer, Jiangsu Hengrui, RA Capital Management, Hansoh Pharmaceutical, GSK plc, Boehringer Ingelheim, Pivotal BioVenture Partners, and Pacific Bridge NY participated. Numerous biotech firms like Adagene, EpimAb Biotherapeutics, and Excalipoint Therapeutics presented their pipelines.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard